Drug Shortage Report for BEOVU
| Report ID | 280293 |
| Drug Identification Number | 02496976 |
| Brand name | BEOVU |
| Common or Proper name | BEOVU 6MG PFS 0.05ML |
| Company Name | NOVARTIS PHARMACEUTICALS CANADA INC |
| Market Status | MARKETED |
| Active Ingredient(s) | BROLUCIZUMAB |
| Strength(s) | 6MG |
| Dosage form(s) | SOLUTION |
| Route of administration | INTRAVITREAL |
| Packaging size | 1 |
| Anatomical Therapeutical Chemical (ATC) code | S01LA |
| Anatomical Therapeutical Chemical (ATC) description | |
| Reason for shortage | Disruption of the manufacture of the drug. |
| Anticipated start date | 2026-04-10 |
| Actual start date | |
| Estimated end date | 2026-09-01 |
| Actual end date | |
| Shortage status | Anticipated shortage |
| Updated date | 2026-03-17 |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 700 RUE SAINT-HUBERT MONTREAL, QUEBEC CANADA H2Y 0C1 |
| Company contact information | [email protected] |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v2 | 2026-03-11 | French | Compare |
| v1 | 2026-03-11 | English | Compare |
Showing 1 to 2 of 2